← Back to headlines
Morgan Stanley Raises Eli Lilly Price Target on Updated Biopharma Model
Morgan Stanley has increased its price target for Eli Lilly and Company (LLY), based on updated assumptions within its biopharma financial model.
17 Apr, 13:38 — 17 Apr, 13:38
Sources
Showing 1 of 1 sources
